Orthofix Medical Inc. Q1 FY2025 earnings call

Massimo Calafiore discussed executing the three-year plan, spine commercial channel optimization with short-term softness but long-term growth potential, new product launches in spine and orthopedics, BGT's strong performance, and orthopedics redefining limb reconstruction with TrueLok Elevate. Julie Andrews reviewed Q1 results, non-GAAP financial measures, margins, cash flow, M6 discontinuation impact, and outlined 2025 guidance including net sales and EBITDA targets.

Global Spinal Implants, Biologics and Enabling Technologies: First quarter pro forma net sales were $104.3 million, with year-over-year growth of 4% on a pro forma same-sales day basis. Bone Growth Therapies (BGT): Revenue grew 7% on a same-sales day basis to $55.1 million in Q1, driven by 8% growth in BGT fracture. Global Orthopedics: Grew 13% to $29.8 million in the first quarter, led by 12% growth in US orthopedics and 14% growth in international orthopedics.

Full-year 2025 net sales expected $808 million to $816 million (implied constant currency growth of 5% midpoint). Non-GAAP adjusted EBITDA expected $82 million to $86 million. Tariff exposure estimated $3 million to $4 million, lower than original estimate. Impact from distributor transitions and $5 million negative impact from US-funded NGO business.

Factors affecting actual results include those in SEC filings, non-GAAP measures, risks from distributor transitions in spine, tariff impacts, and ongoing obligations related to M6 discontinuation.

Q: Could you talk about the rationale for spine channel optimization, timeline, and implications for long-range plan?

A: Massimo said they're accelerating transformation by investing in larger commercial partners, with short-term pain but long-term growth potential.

Q: How are you maintaining adjusted EBITDA while lowering top line?

A: Julie Andrews mentioned focus on return-on-investment, right-sizing shared service organization, and delivering on synergies.

Q: Break down guidance buckets and Q1 impact?

A: Julie Andrews said $5 million from US-funded NGO, remainder from spine/biologics channel disruption, with some impact seen in Q1 but majority in Q2.

Q: Details on AccelStim 2.0 and TrueLok System?

A: Massimo said AccelStim 2.0 integrates with STIM onTrack, and TrueLok System is in limited clinical release with strong interest and 90 cases completed